Targeted Network Meeting
Schizophrenia: beyond dopamine and psychosis

Negative symptoms still represent an unmet need in the treatment of patients with schizophrenia. Their pathophysiological mechanisms have not been elucidated yet, and it is largely acknowledged that they do not respond to antipsychotic treatments and interfere with patients' functional recovery. Diversities among research groups in concepts, assessment instruments and experimental models relevant to negative symptoms may have hindered progress in this research area. The Targeted Network Meeting “Schizophrenia: beyond dopamine and psychosis” (Paris September 6, 2017) has been designed to bring together leading experts of clinical assessment, pathophysiological models and treatment of negative symptoms to review advances and challenges of the research field, overcome methodological pitfalls and create the basis for large scale research projects
coordinator: Dieter Naber, Germany
Wednesday 6 September 2017

08:00 - 15:30

Room 342B
08:00 - 08:15 Introduction
 coordinator: Silvana Galderisi, Italy
08:15 - 09:50The relevance of reward related deficits to avolition and asociality
 chair: Silvana Galderisi, Italy
 speakers: Deanna Barch, United States
 Armida Mucci, Italy
 discussant: Stefan Kaiser, Switzerland
09:35 - 09:50General discussion
09:50 - 10:20Coffee break
10:20 - 11:55Animal models of asociality and avolition
 chair: Oliver Howes, United Kingdom
 speakers: Joanna Neill, United Kingdom
 Colm O'Tuathaigh, Ireland
 discussant: Merce Correa, Spain
11:40 - 11:55General discussion
11:55 - 12:55Lunch
12:55 - 15:00Asociality and avolition: the impact of antipsychotic drugs and promising treatment approaches
 chair: Dieter Naber, Germany
 speakers: Oliver Howes, United Kingdom
 Michael Davidson, Israel
 discussant: István Bitter, Hungary
14:25 - 15:00General discussion and closing